TOKYO -- Japan's Fujifilm Holdings said it was "extremely disappointed," after government officials deferred approval of its Avigan treatment for COVID-19, setting back the company's global ambitions for the drug.
Pharmaceuticals
Fujifilm's Avigan hopes hit after Japan puts COVID drug on hold
Health ministry panel says efficacy difficult to judge from available data
